{"id":42949,"date":"2025-10-09T15:52:31","date_gmt":"2025-10-09T07:52:31","guid":{"rendered":"https:\/\/flcube.com\/?p=42949"},"modified":"2025-10-09T15:52:32","modified_gmt":"2025-10-09T07:52:32","slug":"roche-secures-fda-approval-for-tecentriq%e2%80%91lurbinectedin-combo-in-es%e2%80%91sclc","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=42949","title":{"rendered":"Roche Secures FDA Approval for Tecentriq\u2011Lurbinectedin Combo in ES\u2011SCLC"},"content":{"rendered":"\n

Roche (SWX: ROG<\/a>, OTCMKTS: RHHBY<\/a>) announced today that the U.S. Food and Drug Administration (FDA) has approved the PD\u2011L1 antibody Tecentriq\u202f(atezolizumab) and its hyaluronidase\u2011conjugated version, Tecentriq Hybreza, in combination with the chemotherapeutic lurbinectedin (Zepzelca) for maintenance therapy of adult patients with extensive\u2011stage small cell lung cancer (ES\u2011SCLC) who remain progression\u2011free after first\u2011line induction with Tecentriq or Tecentriq Hybreza, carboplatin and etoposide (CE).<\/p>\n\n\n\n

First\u2011In\u2011Class Maintenance Regimen for a High\u2011Risk Disease<\/strong>
This FDA decision marks the first and only approved combination therapy for first\u2011line maintenance treatment of ES\u2011SCLC\u2014a disease historically limited by short survival and few therapeutic options. The pivotal Phase\u202f3 IMforte study underpins the approval, demonstrating that the Tecentriq\u2011lurbinectedin regimen reduced the risk of disease progression or death by 46\u202f% and the risk of death by 27\u202f% versus Tecentriq maintenance alone.<\/p>\n\n\n\n

Key Efficacy Milestones<\/strong>
After 3.2\u202fmonths of induction therapy, median overall survival (OS) for the Tecentriq\u2011plus\u2011lurbinectedin cohort was 13.2\u202fmonths compared with 10.6\u202fmonths for Tecentriq alone. Independent\u2011assessment median progression\u2011free survival (PFS) reached 5.4\u202fmonths versus 2.1\u202fmonths, respectively. Safety profiles remained consistent with the known characteristics of both Tecentriq and lurbinectedin, reinforcing the regimen\u2019s clinical viability.<\/p>\n\n\n\n

Market Implications<\/strong>
Roche\u2019s approval expands its portfolio in the rapidly evolving lung\u2011cancer landscape, positioning the company to capture a larger share of the maintenance\u2011therapy market for ES\u2011SCLC. The combination therapy\u2019s superior efficacy metrics may translate into a competitive advantage as oncologists seek durable disease control for high\u2011grade SCLC patients.-Fineline Info & Tech<\/a><\/p>\n\n\n\n